Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
तुलना करने के लिए मीट्रिक्स | IMNM | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधIMNMपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −11.2x | −4.0x | −0.5x | |
PEG अनुपात | −0.22 | −0.14 | 0.00 | |
क़ीमत/बुक | 9.5x | 2.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 258.6x | 184.4x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | 54.0% | 135.3% | 46.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | −1.6% | 5.4% | अनलॉक करें |